2-(methylamino)-N-phenylacetamide | 31110-53-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(methylamino)-N-phenylacetamide
• 英文别名: N-phenyl-2-(methylamino)acetamide；α-Methylamino-acetanilide；Methylamino-acetanilid
• CAS: 31110-53-9
• 化学式: C₉H₁₂N₂O
• mdl: MFCD02933455
• 分子量: 164.207
• InChiKey: GPKJKIOOIVUFMI-UHFFFAOYSA-N

物化性质

• 沸点：
  337.3±25.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(methylamino)-N-phenylacetamide 、 2-氯-5,6,7,8-四氢喹啉-3-甲腈 在 potassium fluoride 作用下， 以 二甲基亚砜 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  3-氨基-2-甲酰胺四氢吡咯并[2,3-b]喹啉的合成

  摘要：

  本文介绍了通过 Thorpe-Ziegler 转化以高效合成方式首次合成 3-氨基-2-甲酰胺吡咯并 [2,3-b] 喹啉和稠环吡咯并吡啶。报道的合成路线允许产生范围广泛的噻吩并吡啶的氮类似物——具有强生物活性但水溶性差的化合物。

  DOI：

  10.1055/s-0036-1588619
• 作为产物：
  描述：

  苯胺 在 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 28.0h， 生成 2-(methylamino)-N-phenylacetamide
  参考文献：
  名称：

  Structure-Based Design, Synthesis, and Antifungal Activity of New Triazole Derivatives

  摘要：

  A series of new antifungal triazole derivatives with phenylacetamide side chain were rational designed and synthesized on the basis of the structural information of lanosterol 14‐demethylase (CYP51). In vitro antifungal activity assay indicated that several compounds showed higher activity than fluconazole. Especially, compound 8h showed excellent inhibitory activity against Candida albicans and Cryptococcus neoformans (MIC = 0.0156 μg/mL), suggesting that it is a promising lead for the development of novel antifungal agents. The binding mode of compound 8h was investigated by flexible molecular docking. It interacted with CACYP51 through hydrophobic and van der Waals interactions.

  DOI：

  10.1111/j.1747-0285.2011.01138.x

文献信息

• [EN] PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS<br/>[FR] PYRIDOPYRIMIDINES EN TANT QU'INHIBITEURS DU RÉCEPTEUR H4 DE L'HISTAMINE
  申请人：FAES FARMA SA

  公开号：WO2020020939A1

  公开（公告）日：2020-01-30

  The invention relates to compounds of formula (I) or pharmaceutically acceptable salts or solvates thereof, to pharmaceutical compositions comprising them and to their use in the treatment and/or prevention of diseases or disorders mediated by histamine H4 receptor.

  该发明涉及式(I)的化合物或其药用可接受的盐或溶剂，以及包含它们的药物组合物，以及它们在治疗和/或预防由组胺H4受体介导的疾病或疾病中的用途。
• METHOD FOR PREPARING OPTICALLY ACTIVE N-METHYLAMINO ACIDS AND OPTICALLY ACTIVE N-METHYLAMINO ACID AMIDES
  申请人：Arie Sachiko

  公开号：US20130041178A1

  公开（公告）日：2013-02-14

  The present invention relates to a method for preparing optically active N-methylamino acids and/or optically active N-methylamino acid amides by subjecting the cells or treatment products of a microorganism belonging to the Mycoplana genus to the hydrolysis with N-methylamino acid amide to give an optically active N-methylamino acid and an optically active N-methylamino acid amide. According to the present invention, optically active N-methylamino acids and optically active N-methylamino acid amides useful as the raw material of pharmaceuticals can be stereoselectively obtained with good efficiency.

  本发明涉及一种通过将属于Mycoplanagenus微生物的细胞或处理产物暴露于N-甲基氨基酸酰胺的水解作用，从而得到一种光学活性的N-甲基氨基酸和一种光学活性的N-甲基氨基酸酰胺的方法。根据本发明，可以高效地立体选择性地获得用作药物原料的光学活性N-甲基氨基酸和光学活性N-甲基氨基酸酰胺。
• Aza-SAHA Derivatives Are Selective Histone Deacetylase 10 Chemical Probes That Inhibit Polyamine Deacetylation and Phenocopy HDAC10 Knockout
  作者：Raphael R. Steimbach、Corey J. Herbst-Gervasoni、Severin Lechner、Tracy Murray Stewart、Glynis Klinke、Johannes Ridinger、Magalie N. E. Géraldy、Gergely Tihanyi、Jackson R. Foley、Ulrike Uhrig、Bernhard Kuster、Gernot Poschet、Robert A. Casero、Guillaume Médard、Ina Oehme、David W. Christianson、Nikolas Gunkel、Aubry K. Miller

  DOI：10.1021/jacs.2c05030

  日期：2022.10.19

  transformed SAHA from an unselective pan-HDAC inhibitor into a specific HDAC10 inhibitor. Optimization of the aza-SAHA structure yielded the HDAC10 chemical probe DKFZ-748, with potency and selectivity demonstrated by cellular and biochemical target engagement, as well as thermal shift assays. Cocrystal structures of our aza-SAHA derivatives with HDAC10 provide a structural rationale for potency, and

  我们报告了第一个充分表征的组蛋白脱乙酰酶 10 (HDAC10) 选择性化学探针，与其他 HDAC 同工酶相比具有前所未有的选择性。HDAC10 使多胺去乙酰化并具有独特的底物特异性，使其在 11 种锌依赖性 HDAC 水解酶中独一无二。从 HDAC10 多胺底物中汲取灵感，我们系统地将一个氨基（“aza-scan”）插入到获批药物 Vorinostat (SAHA) 的己基连接部分中。这种单原子置换 (C→N) 将 SAHA 从非选择性泛 HDAC 抑制剂转化为特异性 HDAC10 抑制剂。aza-SAHA 结构的优化产生了 HDAC10 化学探针DKFZ-748, 具有通过细胞和生化目标参与以及热转移分析证明的效力和选择性。我们的 aza-SAHA 衍生物与 HDAC10 的共晶结构提供了效力的结构原理，并且化学蛋白质组学分析证实了DKFZ-748在 HDAC 药物靶标景观中具有出色的细胞
• Cyclic imide derivatives
  申请人：GLAXO INC.

  公开号：EP0520573A1

  公开（公告）日：1992-12-30

  Compounds are described of the formula wherein:    R¹ is C₃₋₆alkyl or C₁₋₃alkylthioC₁₋₃alkyl;    R² is an optionally substituted C₁₋₆alkyl or C₁₋₆alkoxy group, aryl, heteroaryl, arylC₁₋₄alkyl, heteroarylC₁₋₄alkyl or a side-chain of a natural α-amino acid;    R³ is hydrogen, C₁₋₆alkyl, CHR⁴COR⁵ (where R⁴ is a side-chain of a natural α-amino acid and R⁵ is hydroxyl, C₁₋₆alkoxy or NHR⁶ where R⁶ represents a hydrogen atom or a C₁₋₆alkyl group) or a group (CH₂)nX (where n is 1 to 6 and X is hydroxyl, C₁₋₄alkoxy, heteroaryl or a group NR⁷R⁸ where R⁷ and R⁸ are each hydrogen or C₁₋₆alkyl or the group NR⁷R⁸ forms a 5 to 7 membered cyclic amine); and    Het is an optionally substituted cyclic imide where the cyclic imide ring system has the formula (i), (ii) or (iii) in which A, B, C and D are each CH or 1 or 2 of A, B, C and D represents N and the others represent CH, and E and F may each independently represent CH or N; and physiologically acceptable salts and solvates thereof. These compounds inhibit metalloproteases involved in tissue degradation. Compounds of the invention may be formulated for use in a variety of conditions involving tissue degradation including arthropathy, dermatological conditions, bone resorption, inflammatory diseases, tumour invasion and multiple sclerosis and related diseases involving myelin degradation, and in the promotion of wound healing.

  所述化合物的化学式为 其中 R¹ 是 C₃₋₆ 烷基或 C₁₋₃ 烷硫基 C₁₋₃ 烷基； R² 是任选取代的 C₁₋₆ 烷基或 C₁₋₆ 烷氧基、芳基、杂芳基、芳基 C₁₋₄烷基、杂芳基 C₁₋₄ 烷基或天然 α- 氨基酸的侧链； R³ 是氢、C₁₋₆烷基、CHR⁴COR⁵（其中 R⁴ 是天然 α- 氨基酸的侧链，R⁵ 是羟基、C₁₋₆烷氧基或 NHR⁶，其中 R⁶ 代表氢原子或 C₁₋₆ 烷基）或基团 (CH₂)nX （其中 n 为 1 至 6，X 为羟基、C₁₋₄烷氧基、杂芳基或基团 NR⁷R⁸，其中 R⁷ 和 R⁸ 各为氢或 C₁₋₆ 烷基或基团 NR⁷R⁸ 形成 5 至 7 个成员的环胺）；和 Het 是任选取代的环状亚胺，其中环状亚胺环系统具有式(i)、(ii)或(iii) 其中 A、B、C 和 D 各自为 CH，或 A、B、C 和 D 中的 1 或 2 代表 N，其它代表 CH，E 和 F 可各自独立地代表 CH 或 N；及其生理上可接受的盐和溶液。 这些化合物可抑制参与组织降解的金属蛋白酶。本发明的化合物可配制用于各种涉及组织降解的疾病，包括关节病、皮肤病、骨吸收、炎症性疾病、肿瘤侵袭和多发性硬化症及涉及髓鞘降解的相关疾病，以及促进伤口愈合。
• Novel anthrapyridone compounds, water-base magenta ink compositions, and ink-jet recording process
  申请人：——

  公开号：US20040239739A1

  公开（公告）日：2004-12-02

  New anthrapyridone compounds represented by the general formula (14): 1 {wherein R represents a hydrogen atom, an alkyl group (optionally substituted with mono- or di-alkylamino group), a lower alkyl group(optionally substituted with a hydroxyl group or a cyano group), or a cyclohexyl group; Y represents a chlorine atom, a hydroxyl group, an amino group, mono- or di-alkylamino group (optionally substituted with a sulfonic acid group, a carboxy group, or a hydroxyl group), an aralkyl- or cycloalkyl-amino group, an alkoxy group, a phenoxy group (optionally substituted with a sulfonic acid group, a carboxy group, an acetylamino group, an amino group, or a hydroxyl group), an anilino group (optionally substituted with a sulfonic acid group or a carboxy group), or a naphthylamino group (optionally substituted with a sulfonic acid group); and X represents a bridging group}; or salts thereof and magenta inks containing the same, which have hues and vividness suitable for ink-jet recording and give records excellent in fastness to light, gas, water and so on.

  通式(14)代表的新型蒽吡啶酮化合物： 1 其中 R 代表氢原子、烷基（可选择被一或二烷基氨基取代）、低级烷基（可选择被羟基或氰基取代）或环己基；Y 代表氯原子、羟基、氨基、单烷基或二烷基氨基（可选择被磺酸基、羧基或羟基取代）、芳基或环烷基氨基、烷氧基、苯氧基（可选择被磺酸基、羧基、乙酰基或羧基取代）、烷基或环己基；或羧基、乙酰氨基、氨基或羟基）、苯胺基（可选择被磺酸基或羧基取代）或萘胺基（可选择被磺酸基取代）；或其盐类，以及含有这些成分的洋红色油墨，它们具有适合喷墨记录的色调和鲜艳度，并具有优异的耐光、耐气、耐水等牢度。